Biotechnology company Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently reported that clinical lab tests conducted with live animals demonstrated that its new, enhanced version of DehydraTECH(TM) can deliver eight times more CBD into the blood and 19 times more CBD into the brain tissue than standard industry formulations (http://cnw.fm/0sJRF). An article discussing the company reads, “LXRP intends to perform more studies on the enhanced DehydraTECH and focus on optimizing implementation regarding product applications for its licensees. . . . In earlier test results, LXRP announced that original or standard DehydraTECH combined with generic nanotech techniques delivers 1,137% more cannabidiol (CBD) into animal brain tissue following oral ingestion than certain existing industry formulations (http://cnw.fm/rCD1R). The tests consisted of oral administration of CBD into 10 male Sprague-Dawley rats.”
To view the full article, visit http://cnw.fm/7qLhM
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. licenses disruptive, patented-delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates, more rapid delivery to the bloodstream, and important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Do you have a questions or are you interested in working with CNW? Ask our Editor